Researching the Effect of Aerobic Exercise on Cancer

Inclusion Criteria

• •Cohort 1: CH
• •CH called by MSK practices as documented by an MSK physician
• •Age ≥18 yrs
• •Completion of all anticancer therapy
• •High risk of cardiovascular disease defined by presence of at least one of the following:
• •* Age ≥60
• •* Prior treatment with chemotherapy
• •* Prior left-sided breast and/or chest wall radiotherapy
• •* Currently receiving or previously received androgen deprivation therapy Prior bone marrow transplant
• •* History of smoking
• •* Currently treated for one or more cardiovascular risk factors (i.e., hypertension, diabetes, hyperlipidemia)
• •Performing less than 150 minutes of structured moderate-intensity or strenuous-intensity exercise per week, as evaluated by self-report
• •Willingness to comply with all study-related procedures
• •Cohort 2: Solid Tumor
• •Patients at risk of harboring circulating tumor DNA as defined by one of the following:
• •* Histologically confirmed stage III (i.e., high risk of recurrence) colorectal cancer within 2 years of completion of all adjuvant therapy.
• •* Histologically confirmed stage III breast cancer with residual disease after neoadjuvant therapy and within 12 months of completing (neo)adjuvant chemotherapy
• •* Patients with metastatic breast cancer and radiographic stable disease or NED for ≥6 months and not currently receiving chemotherapy (endocrine therapy and anti-HER2 antibodies allowed)
• •Age ≥ 18 yrs
• •Performing less than 150 minutes of structured moderate-intensity or strenuous-intensity exercise per week, as evaluated by self-report
• •Willingness to comply with all study-related procedures
• •Cohort 3: Active Surveillance
• •Men with histologically confirmed localized prostate cancer undergoing active surveillance
• •Age ≥ 18 yrs
• •Performing less than 15 minutes of structured moderate-intensity or strenuous-intensity exercise per week, as evaluated by self-report
• •Willingness to comply with all study-related procedures
• •Cleared for exercise participation as per pre-screening clearance via PAR-Q+
• •Cohort 4: Lynch Syndrome
• •Age ≥18 yrs
• •Hereditary colorectal cancer syndrome, specifically Lynch syndrome, defined by the presence of a deleterious germline mutation in the MLH1, MSH2, MSH6, PMS2 or EPCAM genes
• •Have a portion of the distal colon or rectosigmoid intact to enable collection of normal mucosa biopsies
• •Performing less than 150 minutes of structured moderate-intensity or strenuous-intensity exercise per week, as evaluated by self-report
• •Willingness to comply with all study-related procedures
• •Cleared for exercise participation as per pre-screening clearance via PAR-Q+
• •Cohort 5: EDD Phase 0a
• •Age ≥18 yrs
• •Receiving investigational agent under an EDD protocol for at least 2 months.
• •Performing less than 150 minutes of structured moderate-intensity or strenuous-intensity exercise per week, as evaluated by self-report
• •Willingness to comply with all study-related procedures
• •Cleared for exercise participation as per pre-screening clearance via PAR-Q+
• •Phase 0b
• •Age ≥18 yrs
• •Newly Within 3 months of initiating investigational agent on an EDD Service protocol
• •Performing less than 150 minutes of structured moderate-intensity or strenuous-intensity exercise per week, as evaluated by self-report
• •Willingness to comply with all study-related procedures
• •Cleared for exercise participation as per pre-screening clearance via PAR-Q+